Non-Hodgkin Lymphoma Therapeutics Market Size, Share, Trends, & Industry Analysis Report By Cell Type (B-cell lymphomas, T-cell lymphoma),By Therapy Type, By Route of Administration, and By Region – Market Forecast, 2025–2034

The Non-Hodgkin lymphoma therapeutics market size is expected to reach USD 18.90 Billion by 2034, according to a new study by Polaris Market Research. The report “Non-Hodgkin Lymphoma Therapeutics Market Share, Size, Trends, Industry Analysis Report: By Cell Type (B-cell lymphomas, T-cell lymphoma), By Therapy Type, By Route of Administration, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Non-Hodgkin lymphoma therapeutics refer to a broad spectrum of targeted treatments designed to address diverse lymphatic cancer subtypes, focusing on efficacy, safety, and prolonged patient survival. These therapies are developed under stringent clinical standards to ensure precision, consistency, and favorable treatment response.

The market growth is fueled by increasing global cancer incidence and the urgent need for effective targeted therapies with improved safety profiles. Advancements in cancer immunotherapy, monoclonal antibodies, and CAR-T cell treatments are enhancing clinical outcomes for relapsed and refractory NHL cases. Rising healthcare investments and supportive regulatory pathways are further accelerating the development and accessibility of next-generation lymphoma therapeutics across major treatment centers worldwide.

Non-Hodgkin Lymphoma Therapeutics Market Report Highlights

Based on cell type, the B-cell lymphoma segment held largest share of the market in 2024, due to its high prevalence and growing availability of targeted treatment options that improve remission rates and long-term survival outcomes.

Based on therapy type, the targeted therapy segment is expected to witness the fastest growth, due to its precision in attacking cancerous cells while minimizing damage to healthy tissue

Based on route of administration, the intravenous segment held the dominant market share in 2024, driven by the widespread use in hospitals and oncology centers for delivering biologics and chemotherapy with controlled dosage and efficacy.

North America accounted for largest share of the global non-hodgkin lymphoma therapeutics market in 2024, fueled by strong healthcare spending and the presence of leading biopharmaceutical companies engaged in lymphoma drug development.

Asia Pacific is expected to grow with a significant CAGR during the forecast period market share, due to the growing cancer burden and increased access to advanced therapies.

A few global key market players include AbbVie Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Janssen Biotech, Inc., Teva Pharmaceutical Industries Ltd., and Verismo Therapeutics, Inc.

Polaris Market Research has segmented the market report on the basis of cell type, therapy type, route of administration, and region:

By Cell Type Outlook (Revenue, USD Billion, 2020–2034)

B-cell lymphomas

T-cell lymphoma

By Therapy Type Outlook (Revenue, USD Billion, 2020–2034)

Chemotherapy

Targeted therapy

Radiation therapy

Other therapy types

By Route of Administration (Revenue, USD Billion, 2020–2034)

Oral

Intravenous

Subcutaneous

By Regional Outlook (Revenue, USD Billion, 2020–2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America Show more